MIN/Sp/AU/CAMH3/6 TB
Page 19
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
74
15
44
57
59
52
42
16
89
37
54
45
51
72
26
44
17
90
64
38
55
64
70
79
55
73
42
26
34
67
76
54
78
75
47
79
55
71
59
-
50
68
80
80
70
73
93
87
73
72
69
82
73
76
74
73
75
55
86
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao
Tome
Principe
Senegal
Seychelles
Sierra Leone
South Africa
Swaziland
Togo
Uganda
UR Tanzania
Zambia
Zimbabwe
AFR
57
21
11
35
-
45
77
40
12
33
-
47
83
49
20
27
-
39
49
-
75
56
65
79
61
-
79
75
74
75
83
-
62
28
13
57
23
53
83
33
58
11
48
49
45
35
35
71
49
19
44
46
53
42
46
44
89
69
60
73
62
52
82
77
66
63
78
69
72
86
71
42
71
73
82
84
68
76
&
4.2.4: Prevalence of Drug Resistant TB
Drug resistant TB constitutes a silent component of the TB epidemic in the
region. Until an outbreak of XDR-TB was reported in early 2006, little attention
was being paid to identification and treatment of drug resistant TB, even
though evidence shows that it exists everywhere it has been surveyed for.
Regular case notification initiated in 2007 yielded 8,474 MDR-TB cases from
28 countries. Four countries, namely, Botswana (2 cases), Lesotho (1 case),
Mozambique (1 case) and South Africa (536) also reported 541 XDR-TB
cases. By the end of 2007, there were still 10 Member States without facilities
for TB culture and drug susceptibility Testing, constituting 78.3% coverage
with culture and drug susceptibility testing coverage by country. Table 4.2.4
shows MDR-TB cases notified by country during 2007, and countries’ status
of treatment programmes for MDR/XDR-TB as of January 2008.